Antisense Oligodeoxynucleotide Technology: Potential Use for the Treatment of Malignant Brain Tumors (Q40770171)

23 September 2017

title

Antisense Oligodeoxynucleotide Technology: Potential Use for the Treatment of Malignant Brain Tumors (English)

1 reference

23 September 2017

Engelhard HH

1 reference

23 September 2017

publication date

1 March 1998

1 reference

23 September 2017

1 reference

23 September 2017

1 reference

23 September 2017

1 reference

23 September 2017

page(s)

163-170

1 reference

Inhibition of Rous sarcoma viral RNA translation by a specific oligodeoxyribonucleotide

23 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1177%2F107327489800500207

Control of oncogene expression by antisense nucleic acids

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327489800500207

Second-generation antisense oligonucleotides: structure-activity relationships and the design of improved signal-transduction inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327489800500207

Antisense oligonucleotides: towards clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327489800500207

Oligonucleotides as therapeutic agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327489800500207

Current concepts in antisense drug design

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327489800500207

Antisense oligodeoxynucleotides as clinical therapeutic agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327489800500207

Recent status of the antisense oligonucleotide approaches in oncology

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327489800500207

The therapeutic potential of antisense oligonucleotides

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327489800500207

Design and application of antisense oligonucleotides in cell culture, in vivo, and as therapeutic agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327489800500207

Progress in antisense oligonucleotide therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327489800500207

Antisense-oligonucleotide therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327489800500207

Gene inhibition using antisense oligodeoxynucleotides

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327489800500207

Pharmacokinetics of antisense oligonucleotides

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327489800500207

Antisense strategy: biological utility and prospects in the treatment of hematological malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327489800500207

Transfection with bFGF sense and antisense cDNA resulting in modification of malignant glioma growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327489800500207

Antisense expression of protein kinase C alpha inhibits the growth and tumorigenicity of human glioblastoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327489800500207

Suppression of glioblastoma angiogenicity and tumorigenicity by inhibition of endogenous expression of vascular endothelial growth factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327489800500207

Antisense oligonucleotides for central nervous system tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327489800500207

Antisense oligonucleotides as therapeutic agents--is the bullet really magical?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327489800500207

Urokinase antisense oligodeoxynucleotides as a novel therapeutic agent for malignant glioma: in vitro and in vivo studies of uptake, effects and toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327489800500207

Pharmacokinetics, biodistribution, and stability of oligodeoxynucleotide phosphorothioates in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327489800500207

Antiproliferative Effect of c-myc Antisense Phosphorothioate Oligodeoxynucleotides in Malignant Glioma Cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327489800500207

Progress in antisense therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327489800500207

In vivo studies with antisense oligonucleotides

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327489800500207

Transforming growth factor-beta-mediated autocrine growth regulation of gliomas as detected with phosphorothioate antisense oligonucleotides.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327489800500207

Oligonucleotide N3'-->P5' phosphoramidates

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327489800500207

Facilitating oligonucleotide delivery: helping antisense deliver on its promise

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327489800500207

Inhibition of leukemia cell proliferation by receptor-mediated uptake of c-myb antisense oligodeoxynucleotides

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327489800500207

Interactions of antisense DNA oligonucleotide analogs with phospholipid membranes (liposomes).

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327489800500207

Antisense technology for cancer therapy: does it make sense?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327489800500207

Triplex-forming oligonucleotide binding represses transcription of the human c-erbB gene in glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327489800500207

Autocrine growth regulation in neuroectodermal tumors as detected with oligodeoxynucleotide antisense molecules

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327489800500207

Specific inhibition of c-sis protein synthesis and cell proliferation with antisense oligodeoxynucleotides in human glioma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327489800500207

Protein kinase C isoform ? overexpression in C6 glioma cells and its role in cell proliferation

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327489800500207

Cell cycle effects of microinjected antisense oligodeoxynucleotides to p34cdc2 kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327489800500207

Antisense approaches to the function of glial cell proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327489800500207

The antiproliferative activity of c-myb and c-myc antisense oligonucleotides in smooth muscle cells is caused by a nonantisense mechanism

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327489800500207

p53 interference and growth inhibition in p53-mutant and overexpressing endometrial cancer cell lines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327489800500207

Contiguous four-guanosine sequence in c-myc antisense phosphorothioate oligonucleotides inhibits cell growth on human lung cancer cells: possible involvement of cell adhesion inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327489800500207

Cell-surface perturbations of the epidermal growth factor and vascular endothelial growth factor receptors by phosphorothioate oligodeoxynucleotides

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327489800500207

Sequence-independent induction of Sp1 transcription factor activity by phosphorothioate oligodeoxynucleotides

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327489800500207

The stability, toxicity and effectiveness of unmodified and phosphorothioate antisense oligodeoxynucleotides in Xenopus oocytes and embryos

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327489800500207

Stability, clearance, and disposition of intraventricularly administered oligodeoxynucleotides: implications for therapeutic application within the central nervous system

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327489800500207

Antisense oligodeoxyribonucleotides: stability and distribution after intracerebral injection into rat brain.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327489800500207

Effects of NMDA-R1 antisense oligodeoxynucleotide administration: behavioral and radioligand binding studies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327489800500207

Evidence for a physiological role for nitric oxide in the regulation of the LH surge: effect of central administration of antisense oligonucleotides to nitric oxide synthase

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327489800500207

Intracerebroventricular administration of angiotensin type 1 (AT1) receptor antisense oligonucleotides attenuate thirst in the rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327489800500207

Intracerebral administration of antisense oligodeoxynucleotides to GAD65 and GAD67 mRNAs modulate reproductive behavior in the female rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327489800500207

Antisense oligodeoxynucleotide-mediated disruption of hippocampal cAMP response element binding protein levels impairs consolidation of memory for water maze training

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327489800500207

Intrastriatal administration of an oligodeoxynucleotide antisense to the D2 dopamine receptor mRNA inhibits D2 dopamine receptor-mediated behavior and D2 dopamine receptors in normal mice and in mice lesioned with 6-hydroxydopamine

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327489800500207

Increased stress-induced adrenocorticotropin response after long-term intracerebroventricular treatment of rats with antisense mineralocorticoid receptor oligodeoxynucleotides.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327489800500207

Specific inhibition of endogenous neuropeptide Y synthesis in arcuate nucleus by antisense oligonucleotides suppresses feeding behavior and insulin secretion

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327489800500207

ICV administration of anti-NPY antisense oligonucleotide: effects on feeding behavior, body weight, peptide content and peptide release

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327489800500207

Mechanisms of ANG II-induced mitogenic responses: role of 12-lipoxygenase and biphasic MAP kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327489800500207

Ablation of transplanted HTLV-I Tax-transformed tumors in mice by antisense inhibition of NF-kappa B

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327489800500207

10.1177/107327489800500207

21 January 2018

Identifiers

DOI

0 references

1 reference